HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Myeloid nuclear differentiation antigen: an aid in differentiating lymphoplasmacytic lymphoma and splenic marginal zone lymphoma in bone marrow biopsies at presentation.

Abstract
The differential diagnosis between lymphoplasmacytic lymphoma (LPL) and marginal zone B-cell lymphoma, particularly splenic type (SMZL), can be challenging on onset of bone marrow biopsy (BMB) since morphology and phenotype are not specific and clinical features can overlap or be mildly developed at diagnosis. The LPL-specific L265P mutation in the MYD88 gene is not available in all laboratories, and genetic aberrancies identified in SMZL (del7q, mutations of NOTCH2 and KLF2) are seldom searched in routine practice. The study aim is to investigate the potential role of myeloid nuclear differentiation antigen (MNDA) expression in this specific differential diagnosis. We report MNDA reactivity in 559 patients with small B-cell lymphoma including bone marrow biopsies from 90 LPL and 91 SMZL cases. MYD88 p.Leu265Pro mutation status was assessed and confirmed as positive in 24 of 90 LPL cases, which served as the test set. MNDA staining was negative in 23 of 24 LPL cases in the test set (96%). In the 157 remaining cases (66 LPL, 91 SMZL), which served as the validation set, the MYD88 p.Leu265Pro mutation was unavailable and MNDA was more frequently expressed in SMZL (p < 0.00001). In addition, immunohistochemical features more consistent with SMZL (i.e., presence of CD23+ follicular dendritic cell meshworks, polytypic plasma cells, DBA44 reactivity) were more often present in MNDA-positive cases (statistically significant for 2 such parameters). On the widest case series so far published focusing on LPL and SMZL immunohistochemical diagnosis at onset of BMB, we demonstrated that MNDA expression significantly support the diagnosis of SMZL. This observation may be of particular help in cases where the MYD88 p.Leu265Pro mutational status and/or SMZL-related genetic aberrations are unavailable.
AuthorsSimona Righi, Domenico Novero, Laura Godio, Clara Bertuzzi, Francesco Bacci, Claudio Agostinelli, Carlo Sagramoso, Maura Rossi, Milena Piccioli, Anna Gazzola, Claudia Mannu, Giovanna Roncador, Elena Sabattini
JournalHuman pathology (Hum Pathol) Vol. 124 Pg. 67-75 (06 2022) ISSN: 1532-8392 [Electronic] United States
PMID35339566 (Publication Type: Journal Article)
CopyrightCopyright © 2022 Elsevier Inc. All rights reserved.
Chemical References
  • Antigens, Differentiation
  • Antigens, Nuclear
  • Biomarkers
  • Myeloid Differentiation Factor 88
Topics
  • Antigens, Differentiation
  • Antigens, Nuclear (genetics, metabolism)
  • Biomarkers
  • Biopsy
  • Bone Marrow (pathology)
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell (pathology)
  • Lymphoma, B-Cell, Marginal Zone (diagnosis, genetics, pathology)
  • Mutation
  • Myeloid Differentiation Factor 88 (genetics, metabolism)
  • Splenic Neoplasms (diagnosis)
  • Waldenstrom Macroglobulinemia (diagnosis, genetics, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: